β-adrenergic receptor

β-adrenergic receptor
David Goodsell · CC BY 3.0 · source
Name	β-adrenergic receptor
Family	G protein–coupled receptors
Ligands	Catecholamines
Gene	ADRB1, ADRB2, ADRB3

β-adrenergic receptor

The β-adrenergic receptor is a class of G protein–coupled receptors that mediate responses to the catecholamines epinephrine and norepinephrine and play central roles in cardiovascular, pulmonary, and metabolic physiology. Important in pharmacology, cardiology, pulmonology, and endocrinology, these receptors are targets for drugs developed and studied by institutions such as Pfizer, GlaxoSmithKline, Bayer AG, and referenced in guidelines from American Heart Association, European Society of Cardiology, and National Institute for Health and Care Excellence. Discovered through work influenced by investigators associated with University of Oxford, Harvard Medical School, and Stanford University School of Medicine, β-adrenergic receptors continue to be central to research in signaling, therapeutics, and genetics.

Structure and subtypes

The receptor belongs to the superfamily of seven-transmembrane helix receptors characterized structurally in studies at Max Planck Society, Rockefeller University, University of Cambridge, Massachusetts Institute of Technology, and Salk Institute and specifically comprises three principal human genes: ADRB1, ADRB2, and ADRB3, each encoded and investigated by laboratories at National Institutes of Health, Wellcome Trust, NIH Clinical Center, Columbia University, and Johns Hopkins University. High-resolution structural information derived from crystallography and cryo-EM produced by consortia including European Molecular Biology Laboratory, Riken, and Stanford University revealed conserved motifs shared with receptors studied by groups at Yale University, UCSF, and University of California, Berkeley, while subtype-selective residues were mapped in comparative studies involving Princeton University, University of Chicago, and Duke University. The β1, β2, and β3 subtypes exhibit differences in ligand binding pockets, G protein coupling interfaces, and intracellular C-terminal tails, described in literature from Nature, Science, Cell, Proceedings of the National Academy of Sciences, and journals associated with American Physiological Society.

Mechanism of action and signal transduction

β-adrenergic receptors primarily couple to stimulatory heterotrimeric G proteins (Gs) to activate adenylyl cyclase, increasing cyclic AMP levels, with mechanistic pathways elucidated in studies at University of California, Los Angeles, University College London, Imperial College London, Johns Hopkins University School of Medicine, and Mount Sinai Hospital. Canonical signaling involves cAMP-dependent protein kinase A (PKA) phosphorylation cascades that modulate ion channels and contractile proteins, a framework advanced by investigators affiliated with Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, Max Planck Institute for Heart and Lung Research, and Karolinska Institutet. Desensitization and internalization are mediated by G protein–coupled receptor kinases and β-arrestins, concepts developed in collaboration between groups at Scripps Research, University of Michigan Medical School, University of Texas Southwestern Medical Center, and Vanderbilt University Medical Center, and have implications for biased agonism studied by teams at Novartis, AstraZeneca, and Roche.

Physiological roles and tissue distribution

β-adrenergic receptors regulate heart rate, contractility, bronchodilation, lipolysis, and thermogenesis, with clinical and basic research contributions from Cleveland Clinic, Mayo Clinic, Karolinska University Hospital, The Johns Hopkins Hospital, and Brigham and Women's Hospital. β1 is enriched in cardiac tissue and was characterized in cardiac physiology studies at Mount Sinai School of Medicine, Beth Israel Deaconess Medical Center, and University of Toronto, whereas β2 predominates in bronchial and vascular smooth muscle as shown in pulmonary research at Royal Brompton Hospital, University of Pittsburgh Medical Center, and Baylor College of Medicine. β3 is expressed in adipose tissue and has been the focus of metabolic research from teams at University of Copenhagen, Weizmann Institute of Science, and Massachusetts General Hospital. Functional roles have been examined in models from National Institutes of Health, European Society for Paediatric Research, and consortia including Human Genome Project collaborators.

Pharmacology and agonists/antagonists

Agonists such as isoproterenol, salbutamol (albuterol), and mirabegron and antagonists including propranolol, metoprolol, and carvedilol were developed and tested by pharmaceutical programs at Roche, GlaxoSmithKline, Boehringer Ingelheim, Eli Lilly and Company, and Merck. Clinical pharmacology and receptor subtype selectivity information have been disseminated through trials registered with Food and Drug Administration, European Medicines Agency, and studies published by investigators at University of Oxford, University College London, Harvard Medical School, and University of Pennsylvania. Concepts of partial agonism, inverse agonism, and biased agonism have been debated in symposia convened at American College of Cardiology, European Respiratory Society, and American Thoracic Society, with translational programs at Stanford Medicine and Yale School of Medicine.

Clinical significance and therapeutic applications

β-adrenergic receptor modulation underlies treatments for hypertension, heart failure, angina, asthma, chronic obstructive pulmonary disease, and overactive bladder, with clinical guidelines authored by American Heart Association, European Society of Cardiology, Global Initiative for Asthma, and American College of Chest Physicians. β-blockers such as metoprolol and carvedilol reduce morbidity and mortality after myocardial infarction in trials sponsored by National Heart, Lung, and Blood Institute, European Medicines Agency, and academic centers including Mayo Clinic and Cleveland Clinic. β2 agonists such as salmeterol and formoterol are central to asthma management per recommendations from Global Initiative for Asthma and British Thoracic Society, while β3 agonists like mirabegron are approved by Food and Drug Administration for overactive bladder in trials involving Boehringer Ingelheim and Astellas. Adverse effects, contraindications, and drug interactions are detailed in formularies maintained by British National Formulary, American Medical Association, and hospital systems such as Johns Hopkins Medicine.

Genetic variation and regulation

Polymorphisms in ADRB1, ADRB2, and ADRB3 influence drug response and disease risk, with genomic analyses performed by consortia including 1000 Genomes Project, UK Biobank, International HapMap Project, Wellcome Trust Sanger Institute, and research groups at Broad Institute and European Bioinformatics Institute. Notable variants such as ADRB1 Ser49Gly and Arg389Gly, ADRB2 Gly16Arg and Gln27Glu, and ADRB3 Trp64Arg have been associated with cardiovascular outcomes, asthma phenotypes, and obesity in population studies coauthored by teams at Framingham Heart Study, NHLBI, Harvard T.H. Chan School of Public Health, and Johns Hopkins Bloomberg School of Public Health. Regulation occurs via transcriptional control, post-translational modifications, and microRNA interactions explored in laboratories at Cold Spring Harbor Laboratory, Institute of Molecular Biology (Austria), Salk Institute, and academic centers such as University of Melbourne.

Category:Receptors